Century Therapeutics (IPSC) shares were up more than 8% in recent Tuesday trading after the company reported Q3 results that beat market expectations.
The firm posted a Q3 net loss of $0.37 per diluted share, narrowing from $0.55 loss a year ago. Analysts polled by Capital IQ expected $0.45 loss per share.
Revenue for the quarter ended Sept. 30 was $791,000, compared with $148,000 a year earlier. Analysts polled by Capital IQ expected $550,000.
The company said it expects its funds will support operations into the H2 of 2026.
Price: 1.37, Change: +0.11, Percent Change: +8.33
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。